AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33055274 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1866
Study 33057585 — intervention group
Group type: EXPERIMENTAL
Intervention: E-nside off-the-shelf multibranched endograft
Number of subjects: 268
Study 33057634 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer testing followed by whole-leg compression ultrasonography (CUS) for patients with positive D-dimer (≥0.5 µg/mL)
Number of subjects: 1397
Study 33057657 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with none-to-trace PVR
Number of subjects: 6463
Study 33057657 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with mild PVR
Number of subjects: 6463
Study 33057657 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with moderate-to-severe PVR
Number of subjects: 6463
Study 33057657 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR with none-to-trace PVR
Number of subjects: 6463
Study 33057657 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR with mild PVR
Number of subjects: 6463
Study 33057657 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR with moderate-to-severe PVR
Number of subjects: 6463
Study 33057657 — intervention group
Group type: COMPARATOR
Intervention: TAVR
Number of subjects: 6463
Study 33057657 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 6463
Study 33057725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID or 10 mg BID
Number of subjects: 414
Study 33057725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (monotherapy or with csDMARDs)
Number of subjects: 414
Study 33057725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (exploratory analysis)
Number of subjects: 414
Study 33057928 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic imaging
Number of subjects: 50
Study 33057928 — intervention group
Group type: COMPARATOR
Intervention: Other imaging modalities
Number of subjects: 50
Study 33058137 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 10812
Study 33058182 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy (n=86)
Number of subjects: 154
Study 33058182 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (n=68)
Number of subjects: 154
Study 33058232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 40
Study 33058232 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 33058496 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cystatin C monitoring
Number of subjects: 0
Study 33058496 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary cystatin C/creatinine ratio
Number of subjects: 0
Study 33058496 — intervention group
Group type: COMPARATOR
Intervention: Radionucleide glomerular exploration
Number of subjects: 0
Study 33058695 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline GDF-15 concentrations
Number of subjects: 123
Study 33058695 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 prognostic value
Number of subjects: 123
Study 33058695 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary end point (admission to ICU or death)
Number of subjects: 123
Study 33059200 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That HEAL (CTH) intervention, a community-engaged, data-driven planning process.
Number of subjects: 67
Study 33059645 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis (PT)
Number of subjects: 101
Study 33059715 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0
Study 33059715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33059838 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33060077 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every 3 weeks for three cycles)
Number of subjects: 0
Study 33060149 — intervention group
Group type: EXPERIMENTAL
Intervention: HX008 200 mg intravenously every 3 weeks plus irinotecan 160 mg/m²
Number of subjects: 58
Study 33060153 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV illness (PCR-confirmed ARTI)
Number of subjects: 1040
Study 33060153 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV ARTI (PCR confirmed)
Number of subjects: 1040
Study 33060153 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV illness
Number of subjects: 1040
Study 33060506 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury stage 1
Number of subjects: 1262
Study 33060506 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury stage 2
Number of subjects: 1262
Study 33060506 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury stage 3
Number of subjects: 1262
Study 33060506 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal history
Number of subjects: 1262
Study 33060506 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes
Number of subjects: 1262
Study 33060506 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypernatremia
Number of subjects: 1262
Study 33060506 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic therapy administration
Number of subjects: 1262
Study 33060506 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury
Number of subjects: 1262
Study 33060529 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-strut cobalt chromium sirolimus-eluting stent (SES, Ultimaster)
Number of subjects: 10875
Study 33060529 — intervention group
Group type: COMPARATOR
Intervention: Thicker strut stainless steel biolimus-eluting stent (BES, Nobori)
Number of subjects: 10875
Study 33061274 — intervention group
Group type: EXPERIMENTAL
Intervention: First cataract surgery (group I)
Number of subjects: 200
Study 33061274 — intervention group
Group type: COMPARATOR
Intervention: Second cataract surgery (group II)
Number of subjects: 200
Study 33061276 — intervention group
Group type: EXPERIMENTAL
Intervention: +3.25 D Tecnis IOL
Number of subjects: 0
Study 33061276 — intervention group
Group type: EXPERIMENTAL
Intervention: +4.00 D Tecnis IOL
Number of subjects: 0
Study 33061341 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients during COVID-19 pandemic
Number of subjects: 489
Study 33061341 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with pre-existing COPD
Number of subjects: 489
Study 33061341 — intervention group
Group type: COMPARATOR
Intervention: COPD patients compared to previous year
Number of subjects: 489
Study 33061347 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised Home-Based Pulmonary Rehabilitation (HBPR)
Number of subjects: 41
Study 33061494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus naltrexone/bupropion medication (breast cancer survivor MeDiet+NB group)
Number of subjects: 72
Study 33061494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet alone (breast cancer survivor MeDiet-only group)
Number of subjects: 72
Study 33061494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus naltrexone/bupropion medication (non-cancer MeDiet+NB group)
Number of subjects: 72
Study 33061500 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanins (320 mg/day)
Number of subjects: 121
Study 33061500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 33061515 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-lateral starting position (RLP)
Number of subjects: 142
Study 33061515 — intervention group
Group type: COMPARATOR
Intervention: Left-lateral starting position (LLP)
Number of subjects: 142
Study 33062061 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 13
Study 33062063 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 131
Study 33062063 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 131
Study 33062199 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33062236 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprotein convertase subtilisin/kexin 9 inhibitor (PCSK9i) therapy
Number of subjects: 0
Study 33062236 — intervention group
Group type: COMPARATOR
Intervention: Empagliflozin
Number of subjects: 0
Study 33062284 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming training using the Interactive Rehabilitation and Exercise System (IREX®)
Number of subjects: 54
Study 33062284 — intervention group
Group type: COMPARATOR
Intervention: Traditional gym-based exercise (TGB)
Number of subjects: 54
Study 33062294 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeCare+® (an evidence-based parenting curriculum augmented with a healthy relationships curriculum)
Number of subjects: 0
Study 33062294 — intervention group
Group type: COMPARATOR
Intervention: SafeCare as usual (control group)
Number of subjects: 0
Study 33062302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic posterior capsular stretch (PPCS)
Number of subjects: 0
Study 33062397 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography (OCTA)
Number of subjects: 593
Study 33062397 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 593
Study 33062627 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 (novel selective potassium-competitive acid blocker)
Number of subjects: 0
Study 33062627 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 33062629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib aspartate 7.13 mg (test formulation)
Number of subjects: 41
Study 33062629 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib citrate 8.08 mg (reference formulation)
Number of subjects: 41
Study 33062629 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (test and reference)
Number of subjects: 41
Study 33062947 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 40 mg every 2 weeks
Number of subjects: 30
Study 33063141 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological testing using venous blood and saliva samples collected in June/July 2020, October/November 2020, and March/April 2021.
Number of subjects: 0
Study 33063141 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-monthly questionnaires covering SARS-CoV-2 symptoms, health, preventive behavior, and lifestyle information.
Number of subjects: 0
Study 33063185 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg doxorubicin (DOX) and 10 mg mitomycin C emulsified 1:2 with ethiodized oil (Lipiodol) during conventional transarterial chemoembolization (cTACE)
Number of subjects: 30
Study 33063185 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol distribution stratified (1 vs. ≥ 2 segments vs. lobar)
Number of subjects: 30
Study 33063912 — intervention group
Group type: EXPERIMENTAL
Intervention: Religiously tailored and ethically balanced education
Number of subjects: 137
Study 33064098 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA decolonization intervention (details not specified)
Number of subjects: 16
Study 33064109 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDiC kit (decolonization toolkit)
Number of subjects: 16
Study 33064109 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop activities
Number of subjects: 16
Study 33064186 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed microbiota transplantation (WMT)
Number of subjects: 100
Study 33064186 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 100
Study 33064577 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid pharmacogenomic testing using the 2MoBiL (Mobile Molecular Biology Laboratory)
Number of subjects: 0
Study 33064819 — intervention group
Group type: EXPERIMENTAL
Intervention: RBD BAT
Number of subjects: 263
Study 33064819 — intervention group
Group type: COMPARATOR
Intervention: Baseline factor activity levels
Number of subjects: 263
Study 33064988 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized neoantigen-based vaccine NEO-PV-01 plus PD-1 blockade
Number of subjects: 82
Study 33066188 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based coagulation service (CS)
Number of subjects: 614
Study 33066188 — intervention group
Group type: COMPARATOR
Intervention: Regular medical care (RMC)
Number of subjects: 614
Study 33066724 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic migraine with medication overuse (CM-MO)
Number of subjects: 55
Study 33066724 — intervention group
Group type: EXPERIMENTAL
Intervention: Detoxification protocol in CM-MO subjects
Number of subjects: 55
Study 33066724 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to detoxification in CM-MO (n=23)
Number of subjects: 55
Study 33066724 — intervention group
Group type: COMPARATOR
Intervention: Episodic migraine (EM)
Number of subjects: 55
Study 33066794 — intervention group
Group type: EXPERIMENTAL
Intervention: One-month dual-antiplatelet therapy (DAPT) followed by 23-month ticagrelor monotherapy
Number of subjects: 0
Study 33066794 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT followed by 12-month aspirin alone
Number of subjects: 0
Study 33066794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 0
Study 33066801 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load in lower respiratory tract (LRT) samples
Number of subjects: 90
Study 33066801 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral shedding duration (time to negativity)
Number of subjects: 90
Study 33067126 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiogenic agents plus EGFR-TKIs
Number of subjects: 1295
Study 33067126 — intervention group
Group type: COMPARATOR
Intervention: EGFR-TKIs alone
Number of subjects: 1295
Study 33067260 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (rtCGM)
Number of subjects: 441
Study 33067273 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurology group
Number of subjects: 223
Study 33067273 — intervention group
Group type: COMPARATOR
Intervention: MRI group
Number of subjects: 223
Study 33067297 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-1 bispecific PSMAxCD3 antibody administered after prophylactic interleukin-6 receptor blockade with tocilizumab (8 mg/kg body weight).
Number of subjects: 0
Study 33067318 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19, an autologous anti-CD19 CAR T-cell therapy
Number of subjects: 1
Study 33067318 — intervention group
Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin (ATG)
Number of subjects: 1
Study 33067379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 33067379 — intervention group
Group type: COMPARATOR
Intervention: Ruxolitinib (JAK inhibitor)
Number of subjects: 0
Study 33067382 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Number of subjects: 29
Study 33067382 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 29
Study 33067633 — intervention group
Group type: EXPERIMENTAL
Intervention: BAX 335 gene therapy (1 of 3 IV doses: 2.0 × 10^11; 1.0 × 10^12; or 3.0 × 10^12 vector genomes/kg)
Number of subjects: 8
Study 33067633 — intervention group
Group type: EXPERIMENTAL
Intervention: BAX 335 gene therapy
Number of subjects: 8
Study 33067633 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid treatment
Number of subjects: 8
Study 33067775 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle index (SMI)
Number of subjects: 646
Study 33067775 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle radiodensity (SMR)
Number of subjects: 646
Study 33067775 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue (SAT)
Number of subjects: 646
Study 33067775 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT)
Number of subjects: 646
Study 33067999 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of children parented (for females)
Number of subjects: 472
Study 33067999 — intervention group
Group type: EXPERIMENTAL
Intervention: Motherhood (for females)
Number of subjects: 472
Study 33067999 — intervention group
Group type: COMPARATOR
Intervention: Number of children parented (for males)
Number of subjects: 472
Study 33068028 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib
Number of subjects: 989
Study 33068284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg orally for 4 weeks followed by 2 weeks off)
Number of subjects: 10
Study 33068794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 10 mg/kg and Pembrolizumab 200 mg every 21 days for up to 35 cycles
Number of subjects: 26
Study 33068794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus Pembrolizumab
Number of subjects: 26
Study 33069228 — intervention group
Group type: EXPERIMENTAL
Intervention: PainAPP tool
Number of subjects: 38
Study 33069648 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolut R/PRO transcatheter aortic valves (TAVs)
Number of subjects: 300
Study 33069648 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 300
Study 33069648 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolut R/PRO TAVs
Number of subjects: 300
Study 33069648 — intervention group
Group type: EXPERIMENTAL
Intervention: TAV-sinus of Valsalva relation
Number of subjects: 300
Study 33069648 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean TAV implantation depth
Number of subjects: 300
Study 33069648 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of factors (Evolut TAV, TAV-sinus of Valsalva relation, implantation depth)
Number of subjects: 300
Study 33069650 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated algorithm analyzing pre-PCI FFR pullback curve
Number of subjects: 516
Study 33069650 — intervention group
Group type: EXPERIMENTAL
Intervention: Major FFR gradient group
Number of subjects: 516
Study 33069650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed FFR gradient group
Number of subjects: 516
Study 33069650 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor FFR gradient group
Number of subjects: 516
Study 33069650 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of major FFR gradient lesion
Number of subjects: 516
Study 33069650 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of minor FFR gradient lesion
Number of subjects: 516
Study 33069849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL)
Number of subjects: 431
Study 33070058 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-tailored dashboards (CTH intervention)
Number of subjects: 67
Study 33070260 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab (200 mg) plus chemotherapy (pemetrexed 500 mg/m2)
Number of subjects: 0
Study 33070307 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 63
Study 33070624 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Number of subjects: 108
Study 33070964 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysglycemia (prediabetes and diabetes)
Number of subjects: 766
Study 33070964 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of fasting glucose (≥5.1 mmol/L)
Number of subjects: 766
Study 33070964 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest 2-hour postload glucose quintile (≥6.9 mmol/L)
Number of subjects: 766
Study 33070964 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemia
Number of subjects: 766
Study 33070964 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin
Number of subjects: 766
Study 33071007 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced infection control procedures
Number of subjects: 2195
Study 33071007 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal protective equipment usage
Number of subjects: 2195
Study 33071007 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 prevalence
Number of subjects: 2195
Study 33071007 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression
Number of subjects: 2195
Study 33071007 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety
Number of subjects: 2195
Study 33071007 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 testing positivity rates
Number of subjects: 2195
Study 33071013 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary 3-hydroxyisovaleryl carnitine (3-HIC) excretion
Number of subjects: 694
Study 33071013 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma biotin
Number of subjects: 694
Study 33071107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pembrolizumab PET/CT
Number of subjects: 108
Study 33071107 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-pembrolizumab PET/CT
Number of subjects: 108
Study 33071107 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FDG-uptake
Number of subjects: 108
Study 33071206 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based blood pressure monitoring
Number of subjects: 45
Study 33071206 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based LDL testing
Number of subjects: 45
Study 33071968 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG Triggering
Number of subjects: 8000
Study 33072090 — intervention group
Group type: EXPERIMENTAL
Intervention: Gal3 knockout (Gal3KO) mice
Number of subjects: 2
Study 33072090 — intervention group
Group type: COMPARATOR
Intervention: Polymyxin B (bactericidal antibiotic)
Number of subjects: 2
Study 33072090 — intervention group
Group type: COMPARATOR
Intervention: Clodronate (macrophage modulator)
Number of subjects: 2
Study 33072126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 1
Study 33072397 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice of robot-assisted upper limb reaching
Number of subjects: 0
Study 33072397 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice of robot-assisted upper limb reaching
Number of subjects: 0
Study 33072397 — intervention group
Group type: COMPARATOR
Intervention: Control week assessments (robot-assisted reaching tasks, Melbourne assessment 2, subscale fluency)
Number of subjects: 0
Study 33072399 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T-cell therapy (CAR-T cell therapy)
Number of subjects: 2
Study 33072399 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient engagement in clinical trial protocol development
Number of subjects: 2